Core One Labs Retains Canada’s Highest-Ranked IP Law Firm to Assist With Patent Filings

Shares :

0
(0)

VANCOUVER, British Columbia, June 18, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce it has retained Smart & Biggar LLP (“Smart and Biggar”) to handle all IP filings for Akome Biotech Ltd. (“Akome”) and Vocan Biotechnologies Inc. (“Vocan”).

LEARN ON THE NEW PSYCHEDELIC OPPORTUNITY PSYKEY INC. ( CEOS : OTC ) | HERE 

Smart & Biggar is Canada’s largest and highest-ranked intellectual property law firm. Smart and Biggar’s award-wining IP team has helped the most successful companies in Canada and around the world protect, enforce and leverage their IP rights to grow their business. For innovative pharmaceutical and life sciences companies, they offer specialized expertise for enforcement of IP rights in Canada through combined strengths in prosecution, regulatory and litigation. With over 100 lawyers, patent agents and trademark agents, Smart and Biggar offer legal expertise and technological knowledge across a wide range of industries and scientific and engineering disciplines, with leaders in every field.

We are very excited to be working with the top IP firm in Canada, who will be assisting us in all of our PCT filings which will protect and strengthen our IP. The psychedelic medicine arena is in its infancy, with many different companies working toward commercially viable psychedelic drugs solutions. At Core One we believe we are at the forefront on some breakthrough psychedelic solutions that will be highly valuable in the future. Engaging the top IP firm in Canada is the first step in creating and protecting the value we intend to create for all shareholders,” stated Joel Shacker CEO of the Company.

About Core One Labs Inc.

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.


Sign up for MORE news updates !


This article is written and published by The Cannabis Stock


Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.


Shares :